Vaccines for low-income countries (Q26824128)

language of work or name

1 reference

April 2013

1 reference

published in

Seminars in Immunology

1 reference

volume

25

1 reference

issue

2

1 reference

page(s)

114-23

1 reference

Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Benefits of influenza vaccination during pregnancy for pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Adjuvants for human vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vaccines against mucosal infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

HIV vaccine design: the neutralizing antibody conundrum

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Reverse vaccinology: developing vaccines in the era of genomics

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Lymphocyte subsets in healthy Malawians: implications for immunologic assessment of HIV infection in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

The challenges of vaccine responses in early life: selected examples

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Coalition against Typhoid (CaT): a new, global initiative to advance typhoid vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

The future of immunisation policy, implementation, and financing

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Emergency vaccination against epidemic meningitis in Ghana: Implications for the control of meningococcal disease in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Human genetic susceptibility to infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

New-generation vaccines against cholera

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Group B Streptococcus: global incidence and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Genetic regulation of immune responses to vaccines in early life

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Control of neglected tropical diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Plasmodium falciparum malaria and Salmonella infections in Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Burden of neonatal infections in developing countries: a review of evidence from community-based studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Shigellosis: the current status of vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vaccines for typhoid fever and other salmonelloses

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Tuberculosis vaccines: beyond bacille Calmette-Guerin

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Evolution, revolution and heresy in the genetics of infectious disease susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vaccines to combat the neglected tropical diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vaccines: the Fourth Century

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Phase II meningococcal B vesicle vaccine trial in New Zealand infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Biological functions and biogenesis of secreted bacterial outer membrane vesicles

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

High yield production process for Shigella outer membrane particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

O:2-CRM(197) conjugates against Salmonella Paratyphi A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Needle-free vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Mucosal immunity to poliovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

The Novartis Vaccines Institute for Global Health: a new initiative for developing vaccines for neglected diseases in developing countries.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

Glycoconjugate vaccine strategies for protection against invasive Salmonella infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.SMIM.2013.05.004

7 January 2021

10.1016/J.SMIM.2013.05.004

Identifiers

DOI

0 references

Fatcat ID

release_vyumpvw2krb7ve6d2wormnmppe

0 references

PubMed publication ID

23757292

1 reference